Shinya Tokunaga

Katsumi Ikeda2
Yoshinari Ogawa2
Kosei Hirakawa1
2Katsumi Ikeda
2Yoshinari Ogawa
1Kosei Hirakawa
Learn More
The treatment goals for metastatic breast cancer (MBC) are prolonging survival and improving the quality of life. Eribulin, a non-taxane tubulin inhibitor, demonstrated improved survival in previous studies and also showed mild toxicity when used in late-line therapy for MBC. We conducted a phase II study to investigate the efficacy of eribulin mesylate as(More)
BACKGROUND Axillary reverse mapping (ARM) is a new technique to preserve upper extremity lymphatic pathways during axillary lymph node dissection (ALND), thereby preventing lymphedema patients with breast cancer. However, the oncologic safety of sparing the nodes identified by ARM (ARM nodes), some of which are positive, has not been verified. We evaluated(More)
  • 1